Get the Stockscreener App
54.23
0.66%
-0.36
Pre-market:
54.87
0.64
+1.18%
Moderna Inc stock is traded at $54.23, with a volume of 6.13M.
It is down -0.66% in the last 24 hours and up +5.55% over the past month.
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 35 mRNA development candidates in clinical studies as of August 2025. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.
See More
Previous Close:
$54.59
Open:
$53.96
24h Volume:
6.13M
Relative Volume:
0.64
Market Cap:
$21.51B
Revenue:
$1.94B
Net Income/Loss:
$-2.82B
P/E Ratio:
-7.4679
EPS:
-7.2617
Net Cash Flow:
$-2.08B
1W Performance:
+2.63%
1M Performance:
+5.55%
6M Performance:
+97.27%
1Y Performance:
+115.80%
1-Day Range:
$51.68
$56.20
1-Week Range:
$51.68
$56.20
52-Week Range:
$22.28
$59.55
Moderna Inc Stock (MRNA) Company Profile
Name
Moderna Inc
Sector
Industry
Phone
(617) 714-6500
Address
325 BINNEY STREET, CAMBRIDGE
Compare MRNA vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MRNA
Moderna Inc
|
54.23 | 21.51B | 1.94B | -2.82B | -2.08B | -7.2617 |
VRTX
Vertex Pharmaceuticals Inc
|
436.59 | 111.05B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
747.36 | 79.01B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
805.38 | 50.08B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
308.43 | 41.15B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
312.31 | 34.67B | 5.36B | 287.73M | 924.18M | 2.5229 |
Moderna Inc Stock (MRNA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-28-26 | Resumed | Barclays | Equal Weight |
| Jan-07-26 | Resumed | UBS | Neutral |
| Dec-12-25 | Initiated | Jefferies | Hold |
| Mar-13-25 | Initiated | Citigroup | Neutral |
| Feb-18-25 | Downgrade | Barclays | Overweight → Equal Weight |
| Jan-29-25 | Downgrade | Goldman | Buy → Neutral |
| Dec-18-24 | Downgrade | Argus | Buy → Hold |
| Dec-10-24 | Resumed | BofA Securities | Underperform |
| Nov-19-24 | Initiated | Berenberg | Hold |
| Nov-18-24 | Upgrade | HSBC Securities | Hold → Buy |
| Nov-15-24 | Initiated | Wolfe Research | Underperform |
| Oct-17-24 | Initiated | Bernstein | Mkt Perform |
| Sep-13-24 | Downgrade | JP Morgan | Neutral → Underweight |
| Sep-13-24 | Downgrade | Jefferies | Buy → Hold |
| Sep-13-24 | Downgrade | Oppenheimer | Outperform → Perform |
| Aug-28-24 | Upgrade | HSBC Securities | Reduce → Hold |
| Aug-07-24 | Upgrade | Deutsche Bank | Sell → Hold |
| Aug-05-24 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Feb-26-24 | Downgrade | HSBC Securities | Hold → Reduce |
| Jan-02-24 | Upgrade | Oppenheimer | Perform → Outperform |
| Nov-29-23 | Initiated | Canaccord Genuity | Hold |
| Nov-03-23 | Upgrade | HSBC Securities | Reduce → Hold |
| Nov-02-23 | Downgrade | Deutsche Bank | Hold → Sell |
| Aug-04-23 | Downgrade | TD Cowen | Outperform → Market Perform |
| Aug-03-23 | Downgrade | Deutsche Bank | Buy → Hold |
| Jul-24-23 | Initiated | William Blair | Mkt Perform |
| Jul-14-23 | Initiated | HSBC Securities | Reduce |
| Jun-26-23 | Upgrade | UBS | Neutral → Buy |
| Apr-26-23 | Initiated | Guggenheim | Neutral |
| Mar-13-23 | Upgrade | TD Cowen | Market Perform → Outperform |
| Mar-02-23 | Initiated | RBC Capital Mkts | Outperform |
| Feb-24-23 | Downgrade | SVB Securities | Market Perform → Underperform |
| Dec-19-22 | Upgrade | Jefferies | Hold → Buy |
| Dec-14-22 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| Oct-21-22 | Upgrade | SVB Leerink | Underperform → Mkt Perform |
| Sep-08-22 | Upgrade | Deutsche Bank | Hold → Buy |
| Feb-01-22 | Upgrade | Redburn | Sell → Neutral |
| Jan-26-22 | Upgrade | Deutsche Bank | Sell → Hold |
| Jan-21-22 | Upgrade | BofA Securities | Underperform → Neutral |
| Jan-21-22 | Initiated | UBS | Neutral |
| Dec-07-21 | Initiated | Cowen | Market Perform |
| Nov-09-21 | Initiated | Wolfe Research | Outperform |
| Oct-22-21 | Initiated | Deutsche Bank | Sell |
| Oct-15-21 | Upgrade | Piper Sandler | Neutral → Overweight |
| Aug-06-21 | Downgrade | Oppenheimer | Outperform → Perform |
| Aug-06-21 | Downgrade | Piper Sandler | Overweight → Neutral |
| Jul-15-21 | Reiterated | Jefferies | Hold |
| Feb-01-21 | Downgrade | BofA Securities | Neutral → Underperform |
| Dec-16-20 | Downgrade | Jefferies | Buy → Hold |
| Dec-16-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Dec-09-20 | Downgrade | Needham | Buy → Hold |
| Nov-23-20 | Initiated | Wells Fargo | Equal Weight |
| Nov-17-20 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Sep-08-20 | Downgrade | SVB Leerink | Mkt Perform → Underperform |
| Jul-23-20 | Initiated | SVB Leerink | Mkt Perform |
| Jul-20-20 | Downgrade | JP Morgan | Overweight → Neutral |
| Jul-13-20 | Initiated | Jefferies | Buy |
| Jun-30-20 | Initiated | Argus | Buy |
| Jun-08-20 | Initiated | Barclays | Overweight |
| Apr-30-20 | Initiated | BMO Capital Markets | Outperform |
| Mar-05-20 | Downgrade | BofA/Merrill | Buy → Neutral |
| Dec-03-19 | Resumed | BofA/Merrill | Buy |
| Oct-25-19 | Initiated | ROTH Capital | Buy |
| Apr-05-19 | Initiated | Chardan Capital Markets | Buy |
View All
Moderna Inc Stock (MRNA) Latest News
Moderna (MRNA) Advances with Phase 3 Study of Influenza Vaccine - GuruFocus
Moderna begins phase 3 trial of H5 bird flu vaccine candidate - Investing.com Canada
Moderna starts late-stage trial of bird flu vaccine in US, UK - Reuters
Moderna Announces Initiation of Phase 3 Study of Investigational mRNA Pandemic Influenza Vaccine Candidate - ACCESS Newswire
High-Yield Autocallable Notes Linked to Moderna (AMUB) — 1-Year Term - Stock Titan
Europe Clears First Flu/COVID Combo Shot From Moderna - Benzinga
Moderna Receives European Commission Marketing Authorization For mCOMBRIAX - TradingView
Moderna: Ec Granted Marketing Authorization f - Moomoo
Moderna (MRNA) Secures EU Approval for mCOMBRIAX Vaccine - GuruFocus
Moderna (MRNA) Secures EU Approval for mRNA Combination Vaccine - GuruFocus
Moderna wins EU approval for combined flu, COVID shot for older adults - Reuters
Moderna wins EC nod for mCOMBRIAX - The Pharma Letter
ESCMID Global 2026: repeat vaccination with mRNA-1010 safe and effective - Clinical Trials Arena
European Commission approves Moderna’s flu-COVID combo vaccine By Investing.com - Investing.com Canada
Moderna (MRNA.US) Receives EU Approval for Influenza and COVID-19 Combination Vaccine for Older Adults - AASTOCKS.com
Moderna wins EU nod for combined COVID, flu shot (MRNA:NASDAQ) - Seeking Alpha
European Commission approves Moderna’s flu-COVID combo vaccine - Investing.com
Cambridge drugmaker wins EU approval for combination shot amid FDA battles - The Business Journals
Moderna Announces Data to be Presented at 2026 ASCO Annual Meeting - ACCESS Newswire
EU approves Moderna's dual flu-COVID vaccine - Breakingthenews.net
Moderna lines up melanoma and myeloma data for ASCO in Chicago - Stock Titan
Moderna Receives European Commission Marketing Authorization for mCOMBRIAX, Moderna's mRNA Combination Vaccine Against Influenza and COVID-19 - ACCESS Newswire
EU clears first single-shot vaccine for flu and COVID in adults 50+ - Stock Titan
Federal Court Reportedly Halts Kennedy's Vaccine Panel, Putting COVID, Flu And RSV Shots At Risk - Benzinga
AACR 2026: Moderna, Revolution, Zymeworks and BeOne showcase new data - BioSpace
Moderna to Present at Upcoming Conferences in May 2026 - The Batesville Daily Guard
Moderna lines up 3 investor conference webcasts in May 2026 - Stock Titan
COVID shots, newer vaccines in limbo after US court halts Kennedy's advisory panel - marketscreener.com
GSK, Moderna Both Ordered To Provide More Info In Vax Fight - Law360
What's Pushing Moderna Stock Higher Today? - Benzinga
After a year of turmoil, cancer researchers see promising signs for mRNA vaccines - KIMT
Moderna's Quarterly Earnings Preview: What You Need to Know - Yahoo Finance
Moderna, Inc. (MRNA) Investor Outlook: Assessing the Biotech Giant Amidst Revenue Decline and Market Volatility - DirectorsTalk Interviews
COVID-19 Vaccine Market is expected to Hit US$ 29.98 billion - openPR.com
Study shows Sanofi's Nuvaxovid better tolerated than Moderna's mNEXSPIKE - marketscreener.com
Moderna Inc stock (US60770K1079): Is the post-COVID pivot strong enough to unlock sustained upside? - AD HOC NEWS
Moderna Impfstoff (Spikevax): Respiratory Pivot Amid Vaccine Demand Shifts - AD HOC NEWS
Moderna Inc. stock (US60770K1034): Is its mRNA pivot beyond COVID strong enough for sustained growth - AD HOC NEWS
Moderna, Inc. Experiences Evaluation Revision Amidst Market Dynamics and Performance Indicators - Markets Mojo
Moderna’s mRNA Melanoma Data And Fast Track Status Shape Oncology Story - Yahoo Finance
Behavioral Patterns of MRNA and Institutional Flows - Stock Traders Daily
Communiqué de presse : ESCMID : Le Nuvaxovid, vaccin contre la COVID-19 de Sanofi, a montré une meilleure tolérance que le mNEXSPIKE dans une étude comparative directe - GlobeNewswire Inc.
Moderna (MRNA) Advances Cancer Therapy Research with Promising D - GuruFocus
Moderna to Present Phase 1/2 Data on Its Investigational Cancer Antigen Therapy mRNA-4359 as First-Line Therapy in Combination with Pembrolizumab in Locally Advanced or Metastatic Melanoma at the 2026 AACR Annual Meeting - Investing News Network
Moderna’s melanoma therapy shows 83% response rate in trial By Investing.com - Investing.com Canada
Moderna’s melanoma therapy shows 83% response rate in trial - Investing.com
In 12 melanoma patients, Moderna combo posted 83% response - Stock Titan
Goldman Sachs Adjusts Moderna Price Target to $43 From $41, Maintains Neutral Rating - marketscreener.com
Kailera Therapeutics secures $625M in IPO, surpassing Moderna's 2018 debut - The Business Journals
What Moderna (MRNA)'s Expedited Flu Vaccine Review And Institutional Support Means For Shareholders - Yahoo Finance
MRNA Stock Quote Price and Forecast - CNN
Moderna Inc Stock (MRNA) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.37%
1.29%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):